NSC348884 is a brand-new and powerful nucleophosmin inhibitor that can disrupt oligomer formation and trigger apoptosis. With an IC50 range of 1.7–4.0 μM against cell proliferation in various cancer cell lines.
Physicochemical Properties
| Molecular Formula | C38H40N10 |
| Molecular Weight | 636.7912 |
| Exact Mass | 636.343 |
| Elemental Analysis | C, 71.67; H, 6.33; N, 22.00 |
| CAS # | 81624-55-7 |
| Related CAS # | 81624-55-7 |
| PubChem CID | 335974 |
| Appearance | Solid powder |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 1001.7±65.0 °C at 760 mmHg |
| Flash Point | 559.6±34.3 °C |
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
| Index of Refraction | 1.768 |
| LogP | 4.74 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 11 |
| Heavy Atom Count | 48 |
| Complexity | 891 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | N1=C(CN(CCN(CC2NC3C(=CC(C)=CC=3)N=2)CC2NC3C(=CC(C)=CC=3)N=2)CC2NC3C(=CC(C)=CC=3)N=2)NC2C1=CC=C(C)C=2 |
| InChi Key | KZOLQEUQAFTQFM-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C38H40N10/c1-23-5-9-27-31(15-23)43-35(39-27)19-47(20-36-40-28-10-6-24(2)16-32(28)44-36)13-14-48(21-37-41-29-11-7-25(3)17-33(29)45-37)22-38-42-30-12-8-26(4)18-34(30)46-38/h5-12,15-18H,13-14,19-22H2,1-4H3,(H,39,43)(H,40,44)(H,41,45)(H,42,46) |
| Chemical Name | N,N,N',N'-tetrakis[(6-methyl-1H-benzimidazol-2-yl)methyl]ethane-1,2-diamine |
| Synonyms | NSC348884; NSC 348884; NSC-348884 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | LNCaP cells (IC50 = 4 μM); Granta cells (IC50 = 1.7 μM) |
| ln Vitro |
NSC348884 (0-6 μM; 24 h) binds to NPM and prevents NPM oligomerization[1]. NSC348884 (0.01-100 μM; 4 d) shows cytotoxicity to cancer cells[1]. NSC348884 (1 μM; 4 d) exhibits cytotoxicity against mantle cell lymphoma[1]. NSC348884 (1-5 μM; 24 h) induces cell apoptosis[1]. NSC348884 (0-5 μM; 0-24 h) upregulates the level of p53[1]. |
| ln Vivo | NSC348884 (50 μg; i.p. once) reduces tumor growth[2]. |
| References |
[1]. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancercells. Oncogene. 2008 Jul 10;27(30):4210-20. [2]. Inhibition of nucleophosmin/B23 sensitizes ovarian cancer cells to antiprogrammed cell death protein-1 ligand therapy. 2022. |
Solubility Data
| Solubility (In Vitro) |
DMSO: 34~100 mg/mL (53.4~157.0 mM) Ethanol: ~100 mg/mL (~157.0 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (3.93 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (3.93 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (3.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5704 mL | 7.8519 mL | 15.7038 mL | |
| 5 mM | 0.3141 mL | 1.5704 mL | 3.1408 mL | |
| 10 mM | 0.1570 mL | 0.7852 mL | 1.5704 mL |